Osteoarthritis sufferers could soon receive effective pain relief and reduced onset from the degenerative disease after Paradigm Biopharmaceuticals (ASX: PAR) reported breakthrough clinical trial results which identified a significant reduction of pain levels from participants using their Zilosul product. The 53-day clinical trial saw testing of the injectable Pentosan-based treatment (iPPS) which demonstrated a conclusive
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.